CGEM
Cullinan Oncology Inc

369
Mkt Cap
$424.74M
Volume
712,012.00
52W High
$17.50
52W Low
$5.68
PE Ratio
-1.95
CGEM Fundamentals
Price
$7.19
Prev Close
$7.35
Open
$7.24
50D MA
$7.05
Beta
1.09
Avg. Volume
1.45M
EPS (Annual)
-$3.11
P/B
0.94
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025 Taiho Oncology and Cullinan...
PR Newswire·28d ago
News Placeholder
More News
News Placeholder
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
Zacks·2mo ago
News Placeholder
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix
Cullinan Therapeutics secured global rights, excluding Greater China, to velinotamig from Genrix Bio, expanding its autoimmune pipeline with a second T cell engager.
Stocktwits·5mo ago
News Placeholder
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20...
PR Newswire·9mo ago
News Placeholder
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. read more...
Benzinga·2y ago
News Placeholder
Commit To Purchase Cullinan Oncology At $7.50, Earn 6.2% Annualized Using Options
Investors eyeing a purchase of Cullinan Oncology Inc (CGEM) stock, but tentative about paying the going market price of 17.15/share, might benefit from considering selling puts among the...
Stock Options Channel·2y ago
News Placeholder
Cullinan Oncology (CGEM, $17.03) Aroon Indicator entered a Downtrend on March 28, 2024.
For the last three days, A.I.dvisor has detected that CGEM's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·2y ago
News Placeholder
Cullinan Oncology (CGEM, $17.74) Aroon Indicator entered a Downtrend on March 27, 2024.
For the last three days, A.I.dvisor has detected that CGEM's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·2y ago
News Placeholder
Cullinan Oncology (CGEM, $16.78) entered Downtrend as Momentum indicator drops below 0 level on Mar 26, 2024
This indicator may be signaling that CGEM's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Tickeron - Stocks·2y ago
News Placeholder
Cullinan Oncology (CGEM, $15.5) Aroon Indicator entered a Downtrend on March 19, 2024.
For the last three days, A.I.dvisor has detected that CGEM's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·2y ago

Latest CGEM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.